IFNB1 and myeloid sarcoma: Indeed, most of the FDA-approved MS disease-modifying therapies (DMTs) including interferon beta, glatiramer acetate (Teitelbaum et al., 1996), natalizumab (Yednock et al., 1992; Steinman, 2005), sphingosine 1-phosphate modulators (Fujino et al., 2003; Tsai et al., 2016), dimethyl fumarate (DMF) (Schilling et al., 2006), and B cell depletion therapies (Matsushita et al., 2008; Weber et al., 2010) have demonstrated benefits in EAE.